ArticleCritical care (London, England)2018
Angiotensin in ECMO patients with refractory shock.
Article in Critical care (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Role of Angiotensin II as a Vasoactive Agent to Treat Distributive Shock With a Focus on Preliminary Data in Pediatric-Aged Patients.Paediatric anaesthesia · 2026Review
- Vasoplegia in Cardiac Surgery and Mechanical Circulatory Support: From Cardiopulmonary Bypass to Advanced Circulatory Support Devices.Journal of cardiovascular development and disease · 2026Review
- Association between timing of angiotensin II administration and outcomes in vasoplegia after cardiac surgery.JTCVS open · 2025Article
- Hydroxocobalamin for the treatment of vasoplegia after lung transplantation: A case series.JHLT open · 2025Article
- Angiotensin-II for vasoplegia following cardiac surgery.Perfusion · 2024Article
- Sepsis-associated acute kidney injury: recent advances in enrichment strategies, sub-phenotyping and clinical trials.Critical care (London, England) · 2024Review
- Use of vasopressors and inotropes in ECMO.Intensive care medicine · 2024Article
- Angiotensin ii therapy in refractory septic shock: which patient can benefit most? A narrative review.Journal of anesthesia, analgesia and critical care · 2024Review
- The medical treatment of cardiogenic shock.Journal of intensive medicine · 2023Review
- The Role of Angiotensin II in Poisoning-Induced Shock-a Review.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2022Review
- A Multicenter Observational Cohort Study of Angiotensin II in Shock.Journal of intensive care medicine · 2022Observational
- Observational
- Angiotensin II in ECMO patients: a word of caution.Critical care (London, England) · 2019Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.